About - Gastroenterologist in Chula Vista

About Dr. Wiener

I am a Board Certified Gastroenterologist in private practice since 1987 in Chula Vista, CA. I was born in El Salvador and am fluent in Spanish, French, and English.

My practice consists of classic private full-service Gastroenterology and Digestive diseases, using the latest diagnostic and therapeutic methods. The diagnostic method always includes a thorough evaluation of the patient’s concerns and medical conditions.

Further Information About Dr. Wiener

The emphasis is on allowing the patient to express concerns and symptoms, in an attempt to obtain a global understanding. For this, I use the Scientific Method and the latest evidence from the accepted medical practice. Diagnostic Procedures include endoscopy, colonoscopy, cancer screening, small bowel video capsule, and Bravo esophageal pH monitoring. Therapeutic modalities include biopsy, polyp removal, ablation of esophageal varices, argon plasma and laser ablation of lesions, office hemorrhoid ablation, Barrx ablation of Barrett’s esophagus, stricture dilation, stent placement, and multiple other options.

Understanding the need for privacy and the difficulty in dealing with many gastroenterology issues, I do my best to keep the process comfortable, reassuring, pain-free and at times humorous. I want my patients to improve their quality of life, prevent disease, acknowledge and understand themselves better. My helpful and friendly staff, and I, look forward to serving you and your family by providing the best possible care.

Specialty:

Gastroenterology (Board Certified)

Special Recognitions:

Dr. Gregory Wiener has received Guardian Angel recognitions from grateful patients and families. Have you and your family received exceptional care from Dr. Wiener? Consider paying tribute to this doctor with a Guardian Angel gift.

Affiliations:

Sharp Hospital Chula Vista
Scripps Hospital
ALFA Surgery Center
Magnolia Surgical Center
Endoscopy Center of Chula Vista

Education:

Medical School: Cetec University, Santa Domingo
Internship: Baylor College of Medicine
Residency: Baylor College of Medicine
Fellowship: Wake Forest University

Treatments And Conditions:

Biopsy
Bloodless medicine
Celiac Disease/Gluten Intolerance
Colitis
Colorectal Cancer Screening
Colonoscopy
Crohn’s Disease
Diverticulitis
Endoscopy
Esophageal Reflux
Fatty Liver
Gastroesophageal Reflux Disease
Heartburn
Hemorrhoids
Irritable Bowel Syndrome
Malabsorption
Peptic Ulcer Disease
Removal of Colon Polyps
Small Intestinal Balloon Enteroscopy
Swallowing Difficulties/Disorders
Ulcer Evaluation/Treatment
Video Capsule Endoscopy

MORE ABOUT DR. GREGORY WIENER

EDUCATION AND TRAINING:

Current Position: 1987 – Present

Principal Investigator

7/85 to 6/87 Fellow in Gastroenterology

Bowman Gray School of Medicine
Winston-Salem, North Carolina 27103
Chief of Section: Donald O Castell, M.D.

1/85 to 6/85 Chief Resident of Medicine

VA Medical Center
Baylor College of Medicine
Houston, Texas 77030
Chief of Department: Robert Luchi, M.D.

1983 to 1985 Resident in Internal Medicine / 1982 to 1983 Intern in Medicine

Baylor College of Medicine
Houston, Texas 77030
Chief of Department: Edward Lynch, M.D.

2/80 to 1982 Cetec University- M.D. degree

Santo Domingo, Dominican Republic

Senior Clerkships:

University of California, San Diego – Pediatrics
Baylor College of Medicine – General Medicine, MICU
University of California, San Francisco- General Surgery: Infectious Disease
Harvard Medical School- Primary Care Surgery: Radiology; Gastroenterology

1975 to 1980 National University of El Salvador Medical School

San Salvador, El Salvador, Central America

1971 to 1975 Hobart and William Smith College (B.S., Biology)

Geneva, New York

PROFESSIONAL LICENSURE:

1985 -present California
1985-2002 North Carolina
1986 -1987 Florida

SPECIALTY CERTIFICATIONS:

1985 American Board of Internal Medicine
1987 American Board of Gastroenterology

ACADEMIC APPOINTMENTS:

1982 Chief Medical Resident

Baylor College of Medicine
Houston, Texas 77030

1985 Clinical instructor in Medicine

Baylor College of Medicine
Houston, Texas 77030

1987 to 1988 Clinical Instructor, Gastroenterology

Mercy Hospital and Medical Center
San Diego, CA 92104

1989 to 2005 Voluntary Clinical Instructor, Gastroenterology and Family Medicine

University of California, San Diego (UCSD)

2005 to present Voluntary Clinical Assistant. Professor, Gastroenterology

University of California, San Diego (UCSD)

MEMBERSHIPS:

1982 American College of Physicians
1985 American Gastroenterology Association
1986 American College of Gastroenterology

HONORARY POSITIONS:

2003 Honorary Consul of El Salvador in San Diego, CA

AWARDS:

1990 American College Gastroenterology Rorer Award for Research Publication
2010 Journal of Voice Best Paper Award in the Clinical Medicine Category

STAFF PRIVILEGES:

1987-2002 Scripps Mercy Hospital, Chula Vista, CA, 91910
1987-2007 Paradise Valley Hospital 2400 E. Fourth Ave, N.C, CA, 91950
1987-present Sharp Chula Vista Medical Center, Chula Vista, CA, 91911
1987-present Mercy Hospital and Medical Center, San Diego, CA, 92103

PRESENTATIONS AT MEDICAL MEETINGS:

Amador, A., & Wiener, G.J. “The Thyroid Nodule.” A review of 200 cases seen at the Hospital Rosales for the past six years. XVI Central American Medical congress, El Salvador, 1975.
Amador, A., & Wiener, G . J. “The Management of the Solitary Thyroid Nodule.” Latin American Congress of Nuclear Medicine and Biology, San Jose, Costa Rica, 1976.
Wiener, G.J., & Wu, W.C., Koufman, J.A., Copper, J.B., Richter, J.E., Castell, D.O., Chronic hoarseness with laryngeal pathology as a manifestation of upright gastroesophageal reflux disease (GERD). American College of Gastroenterology, Atlanta, Georgia October 1986 (American Journal of Gastroenterology, 1986; 81, 848A).
Wiener, G.J., & Wu, W.C., Koufman, J.A., Copper, J.B., Richter, J.E., Castell, D.O., Laryngeal pathology may be caused by gastroenterology reflux (GER). An ambulatory pH study. World Congress of Gastroenterology. Rio de Janeiro, Brazil, September 1986 (Digestive Diseases and Science, 1986: 31:10).
Arem, R., Kaplan, M.M., Wiener, G. J., G.J., G.J. reichlen, S. Tissue thyroxin and triiodothyronine concentrations in human nonthyroidal illness. American Thyroid Association Meeting. September 1986.
Wiener G.J., Morgan, T.M., Wu, W.C., Copper, M.B., Castell, D.O., Richter, J.E. Ambulatory 24-hour esophageal pH monitoring: Reproducible test for gastroesophageal reflux (GER). (Gastoenterology, 1987; 92: 1694A) 1987 National AGA Meeting. 1987, Chicago (gastroenterology 1987; 92:1695A).
Wiener, G.J., Koufman, J.A., Wu, W.C., Richter, J.E., Copper, J.B., Castell, D.O., The pharyngoesophageal dual ambulatory pH probe for evaluation of atypical manifestations of gastroesophageal reflux (GER) Gastroenterology, 1987; 92:1694A) 1987 National AGA Meeting.
Wiener, G.J., Copper, J.B., Wu, W.C., Richter, J.E., Castell, D.O. The symptom index (SI); an endogenous 24-hour provocative test for symptoms of gastroesophageal reflux (GER). Gastroenterology, 1987; 92:1694A). 1987 National AGA Meeting.
Wiener, G.J., Is the manometric definition of the LES position mandatory for accurate positioning of the pH electrode? Fifth World Congress of the International Organization of Statistics studies on Disease of the Esophagus. Paris September 1996.
Wiener, G.J., Dx-pH Measurement System: A Sensitive Device for
Detecting Liquid and Aerosolized Supraesophageal Gastric Reflux (SEGR). DDW oral presentation, Los Angeles, CA 2006
Wiener GJ, Tsukashima R, Kelly C, Wolf EH, Schmeltzer ME, Bankert CS, Fisk L: Dx–pH measurement System: A Sensitive Device for Detecting Liquid and Aerosolized Supraesophageal gastric Reflux (SEGR). Gastroenterology 130(4) Suppl S2:A-115,2006.
B. Misra, J. Curran, H. Herfarth, K. Jagarlamudi, C. Oneto, B.R. Bhandari, G. Wiener, D. Kerman, A. Moss, R. Pomerantz, J. Zhao, P. Bernardo, S. Simmons, L. Diao, E. O’Brien, M. Henn, and M. Trucksis* SER-287, An Investigational Microbiome Therapeutic, induce remission and endoscopic improvement in a Placebo-Controlled, Double-Blind Randomized trial in patients with active mild-to-moderate Ulcerative Colitis (2922751), Presentation during Digestive Disease Week® (DDW) 2018 at Walter E. Washington Convention Center, Washington, DC, June 2-5, 2018.
Thomas L. Abell, MD, Lazaro M. Garcia, MD, Gregory Wiener, MD, John M.Wo, MD, Robert S. Bulat, MSc MD Ph.D. FRCPC, Neil Smith, PharmD, Improved Gastric Accommodation in Women with Moderate or Severe Diabetic Gastroparesis Randomized to Oral CNSA-001 (Sepiapterin) versus Placebo Poster 20-1162 GAS-001_DDW_v2 Presentation at DDW2020

PUBLICATIONS:

Wiener, G.J., Copper, J.B, Koufamn, J.A., Richter, J.E., Castell, D.O. Is hoarseness an atypical manifestation of gastroesophageal reflux? An ambulatory 24- hour pH study.
Gastroenterology, 1986; 80:A1691
Wiener, G.J., & Castell, D.O. Evaluation of the patient with noncardiac chest pain. Diagnosis, 1986, 8:10, cover article.
Wiener, GJ., Koufman, JA., Wu W.C., et al. The pharyngoesophageal dual ambulatory pH probe for evaluation of gastroesophageal reflux (GER). Gastroenterology 1987; 92:1694 (abstract)
Peters, L., Wiener, G.J., et al. Adult Reye’s syndrome: a case report, review of the literature. Archives of Internal Medicine, 1986; 146:2401-2403
Reid, C.L. Wiener, G.J., Richter, J.E., Cox, D., Geisinger, K. Diffuse hepatocellular dysplasia and carcinoma associated with M-Malton variant of alpha-1-antitrypsin. Gastroenterology, 1987; 94:1-7
Koufman, J.A., Wiener, G.J., Reflux laryngitis and its sequelae: the diagnosis role of ambulatory 24-hour pH monitoring. Journal of Voice, 1988; 1:78-79
Wiener, G.J., Richter, J.e., Copper, P.A, Wu W.C., Castell, D.O. The Symptom Index: A clinically important parameter of ambulatory 24-hour esophageal pH monitoring. The American Journal of Gastroenterology, 1988; 83:353-361
Wiener, G.J., Morgan, T.M., Copper, J.B., et al. Ambulatory 24-hour esophageal pH monitoring: Reproducibility and Variability of pH parameters. Dig. Dis. Sci., 1988.
Wiener, G.J., Koufman, J.A., Copper, J.B., Richter, J.E., Castell, D.O. Chronic hoarseness secondary to gastroesophageal and pharyngeal pH probes. American Journal of Gastroenterology, 1989, 84:1503-1508.
Arem, R., Wiener, G.J., Kaplan, S.G., et al. Reduced Tissue Thyroid Hormone Levels in Fatal Illness. Metabolism, 1993; Vol 42, No 9: 1102-1108
Wiener, G.J. Is Manometric definition of the LES position mandatory for accurate positioning of the pH electrode? O.E.S.O: The Esophagogastric Junction
Guli, R., Galmiche, G.C., Jamieson, C.et.al. John Libbey Eurotext, Montrouge, France:1998.
Wiener, G.J. Re: Fouad et.al. – GERD. American Journal of Gastroenterology, 1999:9; 4:3658
Wiener, G.J., Complications caused by the tip of Gastroenterology tubes and Foley Catheters. American Journal of Gastroenterology, 1999; 94:3656
Wiener GJ, Bankert CS, Kelly C, Fisk L, Schmeltzer ME, Wolf EH, Tsukashima R: Dx–1 A New Device for Detecting Supraesophageal Gastric Reflux (SEGR). Am J Gastroenterol (100)(9): S26,2005.(poster)
Wiener, GJ, et al. Dx-pH Measurement System: A Sensitive Device for Detecting Liquid and Aerosolized Supraesophageal Gastric Reflux (SEGR)
[abstract] Gastroenterology. 2006;130:4 (suppl 2):A115.
Wiener, Gregory. Detecting Supraesophageal Reflux: Advances for Managers of Respiratory Care. 2006; 15-3:47.Wiener, Gregory et al. Oropharyngeal pH Monitoring for the Detection of Liquid and Aerosolized Supraesophageal Gastric Reflux. Journal of Voice, 2009, Vol 23, No. 4, pp 498-504
David Y. Graham, MD; Yamil Canaan, MD; James Maher, MD; Wiener, G.J., MD; Kristina G.Hulten, Ph.D.; Ira N.Kalfus, MD. Re: Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: Double-Blind, Randomized, Controlled Trial (ERADICATE Hp2) (M19-3734)
Miner Jr PB, Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol.2017; doi:10.1038/ajg.2016.611

CLINICAL RESEARCH CERTIFICATIONS:

Investigator Training for Medical Research: University of Rochester School of Medicine and Dentistry and Western Institutional Review Board (WIRB), May 4, 2001.
Shipping Infectious Substances (IATA and DOT) Online Training. Eduwhere July 2009 and July 2011. Inc Research 19Sep2016
CITI CERTIFICATION Basic Course in the Protection of Human Subjects and Good Clinical Practices/ University of Miami (Scripps Hospital Affiliation Program.) October 2012
NIDA Clinical Trials Network: GCP Training Certificate 15 July 2016
INC Research: GCP Training, Revision 2 Changes, and Refresher Course Certificate 28Oct2017

CLINICAL TRIALS-INVESTIGATOR:

Principal Investigator: A Randomized Study of Oral Lobucavir vs. Alpha Interferon in Subjects Chronically Infected with Hepatitis B Virus. June 1998- April 1999. (1 patient enrolled, Sponsor canceled study).
Principal Investigator: A Multicenter, Randomized, Double-Blind, Safety and Efficacy Study of H 199/18 for the Eradication of Helicobacter pylori in Subjects with Active Duodenal Ulcer or History of Duodenal Ulcer Disease. October 1998- April-1999. (Three patients enrolled and screened)
Principal Investigator: A twelve-week randomized, double-blinded, placebo-controlled study of the efficacy and tolerability of Aloseteron Hydrochloride 1mg twice daily for control of bowel urgency in patients with diarrhea-predominant irritable bowel syndrome. Protocol: s3b30011 (1999-2000) (8 screened and 2 enrolled)
Principal Investigator: Aciphex Post Marketing Fast Trial. (10 patients enrolled and screened) (2000)
Principal Investigator: A Comparative Efficacy Study of esomeprazole Magnesium 40mg and Lansoprazole 30mg in patients with erosive esophagitis. (Protocol 267) September 2000- December 2000. (32 patients enrolled and 5 screen failures).
Principal Investigator: A Double-Blinded, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Safety and Efficacy of 2 mg TID of Cilansetron Over 12 Weeks Followed by a 4-week re-randomized treatment of period in diarrhea-predominant Irritable Bowel Syndrome Subjects. (12 enrolled, 4 screens failed)
Principal Investigator: A Randomized Double-Blind Trial Comparing the Early Profile of Heartburn Relief Associated with Rabeprazole, 20 mg Once Daily vs. Omeprazole, 20mg Once Daily in Gastroesophageal Reflux Disease Patients with an Acute or Documented History of Erosive Esophagitis. (23 enrolled, 4 screen failures)
Principal Investigator: A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of repeated treatment with tegaserod 6 mg BID and placebo in female patients with irritable bowel syndrome with constipation (IBS-C) (20 patients enrolled and 23 patients screened)
Principal Investigator: A Twelve-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5mg QD, 1mg QD and 1mg BID of Alosetron in Female Subject with Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy
Principal Investigator: Dx-1 Non Invasive pH Measurement Device Study. Sept 2004-Oct 2005
Principal Investigator: A 12-Week Multicenter, Double-Blind, Randomized Efficacy and Safety Study of Lubiprostone for the treatment of Constipation Predominant Irritable Bowel Syndrome (PRA International Trial)
Principal Investigator: A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR – Studies T-EE04-084, TGD-04082, T-EE04-086, T-GI04-088, TGI05-137, TEE05-135 (6 STUDIES- 48 patients enrolled, 25 screen failures) Nov.2005-2006
Principal Investigator: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Renzapride in Women with Constipation Predominant Irritable Bowel Syndrome. June 2007
Principal Investigator: Gastrointestinal (GI) Randomized event and safety Open-Label NSAID Study (GI-REASONS): A Randomized Open-Label, Blinded Endpoint, Parallel-Group Trial of GI Safety of Celecoxib Compared with Non-Selective Nonsteroidal Anti-inflammatory 22 Drugs (NSAIDS) in Osteoarthritis Patients Protocol A3191331. Jan. 2007-2008.
Principal Investigator: Multicenter, randomized, placebo-controlled, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid–induced Bowel Dysfunction..2008.
Principal Investigator: A Multicenter, randomized, placebo-controlled, double-blinded study on the efficacy and safety of SPI-8811 for the prevention of nonsteroidal anti-inflammatory drug–induced gastroduodenal injury in patients with osteoarthritis and/or rheumatoid arthritis. 2-12/2008.
Principal Investigator: A Randomized Double-Blind parallel study of Rabeprazole Extended-release 50mg versus Esomeprazole 40 mg for healing and symptomatic relief of mild to moderate erosive gastroesophageal reflux disease (GERD). 7/2008 -6/2009 (30 screened/9 randomized)
Principal Investigator: A Randomized Double-Blind parallel study of Rabeprazole Extended-release 50mg versus Esomeprazole 40 mg for healing and symptomatic relief of moderate to severe erosive gastroesophageal reflux disease (GERD). 3/2008 -6/2009 (20 screened/10 randomized)
Principal Investigator: A Randomized Double-Blind parallel study and of Rabeprazole Extended-release 50mg versus Esomeprazole 40 mg for maintenance of erosive gastroesophageal reflux disease (GERD). 3/2008 -6/2009 (7 screened/7 randomized)
Principal Investigator: A Phase 3, Randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin 550 mg TID in the treatment of subjects with non – constipation irritable bowel syndrome. 11/08 -4/2009 (5 screened/4randomized)
Principal Investigator: A phase 3, randomized double-blind, placebo-controlled, parallel-group trial of linaclotide administered orally for 12 weeks followed by a 4-week randomized withdrawal period in patients with chronic constipation. 1/09 (8 screened/1 Randomized)
Principal Investigator: An Open-label, Long-term Safety Study of Oral Linaclotide Administered to patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation. 1/09 – 09/2011 (6 screened/4 randomized)
Principal Investigator: A Phase III, Randomized, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis 2009-04/2012 (11 screened/8 randomized)
Principal Investigator: A phase 3, randomized double-blind, placebo-controlled, parallel-group trial of linaclotide administered orally for 26 weeks with Irritable Bowel Syndrome with constipation. 9/2009 (17 screened/1 randomized)
Principal Investigator: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS). 9/2010 – 3/2013 (39 screened/9 randomized)
Principal Investigator: A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers April 2010 – 03/2012 (17 screened/9 randomized)
Principal Investigator: A Phase 3, Randomized, double-blind placebo-controlled multicenter study to assess the efficacy and safety of budesonide foam ( 2mg/25ml bid for 2 weeks, followed by 2mg/25 ml QD for 4 weeks) versus placebo in subjects with active mild to moderate ulcerative proctitis or proctosigmoiditis: August 2010- June 2013(9 screened/3Randomized)
Principal Investigator: A Phase 3, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects with Active Ulcerative Proctitis or Proctosigmoiditis: September 2011 – September 2013(1 randomized)
Principal Investigator: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, 28-Day Repeat, Oral, Dose-Ranging Study to Assess the Safety and Pharmacodynamic Effects of SP-304 in Patients with Chronic Idiopathic Constipation: October 2011 –February 2013 (40 screened/20 randomized)
Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome: May 2012 – February 2014(14 screened/ 7 randomized)
Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome – Open Label: June 2013 – February 2014(3 screened/ 2 randomized
Principal Investigator: A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhea (IBS-D): June 2012 – June 2014 (34 screened/17 enrolled)
Principal Investigator: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): November 2012-ongoing (14 screened/2 randomized)
Principal Investigator: A Phase 3, Double-Blind, Multi-Center, Placebo-Controlled Maintenance Trial Designed to Evaluate the Efficacy and Safety of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy: March 2013-November 2014 ( 8 screened/4 randomized )
Principal Investigator: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults taking Opioid Therapy for Chronic Non-Cancer Pain: May 2013 – September 2013 ( 3 screened/2 randomized )
Principal Investigator: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5mg and 10mg for 26 weeks: July 2013 – June 2014 ( 15 screened/3 randomized )
Principal Investigator: A Multi-Center, Open-Label, Safety and Tolerability Extension Trial of 5mg and 10g Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation: March 2014 – March 2014(3 randomized)
Principal Investigator: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose. Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): December 2012 – May 2014 ( 39 screened/10 randomized )
Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects with Early Decompensated Liver Cirrhosis: September 2013 – ongoing (20 screened/10 randomized)
Principal Investigator: A Randomized, 12 Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0) in Patients with Chronic Idiopathic Constipation (CIC3). November 2013 – ongoing (55 screened/26 randomized to date)
Principal Investigator: An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC).September 2013 – ongoing (23 rollovers)
Principal Investigator: A 12-week double-blind, randomized, placebo-controlled, parallel-group phase III study, followed by a 4-week randomized withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhea (IBS-D). Study Code: NAK-06; Study Acronym: IRIS-3: Ibodutant for Relief of Irritable Bowel Syndrome: March 2014 – ongoing (6 screened/1 randomized to date) NCT02107196
Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis.August2014-October 2014 (12 screened)
Principal Investigator: (Ironwood Gastroparesis) ICP-112-202; A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients with Diabetic Gastroparesis. November 2014 – ongoing (63screened/12 randomized)
Principal Investigator: A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients with Irritable Bowel Syndrome with Constipation (IBS-C). December 2014 – July 2015 (9 screened/4 randomized)
Principal Investigator: (Sucampo IBS-M/IBS-U) A Randomized, Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Lubiprostone in Adult Subjects With Mixed or Unsubtyped Irritable Bowel Syndrome (IBS-M/IBS-U) February 2015 – ongoing NCT02544152
Principal Investigator: (Ironwood IBS-C) A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) February 2015 – July 2015 ( 9 screened/4 randomized) D5630C00001
Principal Investigator: (Ironwood CIC) A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ugs or 145 ugs) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation February 2015- October – 2015 ( 32 screened/18 randomized) (CIC) NCT02291679
Principal Investigator: (Shire EOE) Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study November 2015 – ongoing (EOE) NCT0260583
Principal Investigator: Ardelyx Pharmaceuticals, A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C) October 2015 – October 2016 (14 screened/ 4 randomized) NCT02621892.
Principal Investigator: Allergan Pharmaceuticals, Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel-Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms with Prior Loperamide Use. January 2017 – ongoing. (8 screened / 4 randomized)
Principal Investigator: Intercept Pharmaceuticals, Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis. December 2016 – ongoing (19 screened / 5 randomized) NCT02548351
Principal Investigator: Octeta Therapeutics, Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Three Dose Levels of MSDC-0602K in Patients with NASH. December 2016 – ongoing. (4 screened/1 randomized) NCT02784444
Principal Investigator: Genfit Pharmaceuticals, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis. November 2016 – ongoing (2 screened) NCT02704403
Principal Investigator: Theravance Pharmaceuticals, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic and Idiopathic Gastroparesis. September 2016 – ongoing. (24 screened/ 11 randomized) NCT02267525
Principal Investigator: SERES Therapeutics, Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study Designed to Evaluate the Safety and Tolerability of SER-287, and to Evaluate the Microbiome Alterations and Pharmacodynamics Associated with 2 Dosing Regimens of SER-287 in Adults Subjects with Mild-to-Moderate Ulcerative Colitis. September 2016 – ongoing. (3 screened/ 3 randomized) NCT02618187
Principal Investigator: Synergy Therapeutics, A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation. August 2016 – ongoing. (10 screened/ 8 randomized
Principal Investigator: Ironwood Pharmaceuticals, A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients with Symptomatic GERD that Persists Despite Treatment with Proton Pump Inhibitors. March 2016 – ongoing. (28 screened/ 7 randomized) NCT02637557
Principal Investigator: Ardelyx Pharmaceuticals, A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C) February 2016 – ongoing. (17 screened/ 10 randomized)
Principal Investigator: Ferring Pharmaceuticals, Phase 3, Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution versus Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Powder for Oral Solution (PREPOPIK) for Colon Cleansing in Preparation for Colonoscopy. February 2017 – Ongoing. (101 Screened / 90 Randomized) one of the top enrolling sites
Principal Investigator: A Randomized Double-Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter pylori (H. pylori) Infection, RHB-105-02 July 2017 – December 2018 (49 Screened/20 Randomized) one of top enrolling sites
Principal Investigator: A Safety and Efficacy Comparison of BLI4700 Bowel Preparationversus an FDA-approved Comparator in Adult Subjects prior to Colonoscopy January 2018 – November 2018 (12 Screened/12 Randomized) one of top enrolling sites
Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis February 2018 – ongoing (6 Screened)
Principal Investigator: RLM-MD-02: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis March 2018 – ongoing (23 Screened)
Principal Investigator: RLM-MD-03: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis July 2018 – ongoing (3 randomized rollovers)
Principal Investigator: RLM-MD-04: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis June 2018 – ongoing (10 screened)
Principal Investigator: MCP-103-312: A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 µg Administered Orally for 12 Weeks in Patients with Irritable Bowel Syndrome with Constipation July 2018 – ongoing (30 screened/16 randomized)
Principal Investigator: C3718-301: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors September 2018 – ongoing (13 screened)
Principal Investigator: Protocol G28-006: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients with Lactose Intolerance August 2018 – ongoing (22 screened)
Principal Investigator: 3152-301-002 – AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic November 2018 – ongoing (7 screened)
Principal Investigator: VP-VLY-686-3301Vanda: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis November 2019 – ongoing (8 screened)
Principal Investigator: Phathom Pharmaceuticals, Inc. A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive Esophagitis November 2019 – ongoing (3 screened)
Principal Investigator: 2018-10, An Evaluation of a Multi-target Stool DNA (mt-DNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now October 2019 – ongoing (47 screened)
Principal Investigator: PBGD 1001, An Open-Label, Multicenter Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Patients with Functional Gastrointestinal Disturbances October 2019- December 2019 (20 screened / 20 randomized)
Principal Investigator: Genentech, Inc. GC41033A Phase II, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of bfkb8488a compared with placebo in patients with non-alcoholic steatohepatitis, February 2019
Principal Investigator: APD371‑202, A Phase 2, Multi‑Center, Randomized, Double‑Blind, Placebo‑Controlled Parallel‑Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects with Irritable Bowel Syndrome Experiencing Abdominal Pain, February 2019
Principal Investigator: Braintree Protocol BLI4900-302, A Safety and Efficacy Comparison of BLI4900 Bowel Preparation versus an FDA-approved Comparator in Adult Subjects prior to Colonoscopy, February 2019
Principal Investigator: Allakos, Inc., A Prospective Study to Identify the Incidence of Eosinophilic Gastrointestinal Diseases and Elevated Tissue Mast Cells among Patients with Chronic Gastrointestinal Symptoms, March 2019
Principal Investigator: Exact Sciences Act Fast 2018-07, Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion, April 2019